Pharvaris NV
NASDAQ:PHVS

Watchlist Manager
Pharvaris NV Logo
Pharvaris NV
NASDAQ:PHVS
Watchlist
Price: 25.09 USD -2.18% Market Closed
Market Cap: 1.6B USD

Relative Value

There is not enough data to reliably calculate the relative value of PHVS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PHVS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

PHVS Competitors Multiples
Pharvaris NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
Pharvaris NV
NASDAQ:PHVS
1.6B USD 0 -8.6 -5.5 -5.5
US
Eli Lilly and Co
NYSE:LLY
982.2B USD 16.5 53.3 35.8 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 5.8 -157.8 0.4 1.9
US
Johnson & Johnson
NYSE:JNJ
526.1B USD 5.7 20.9 17.1 22.2
CH
Roche Holding AG
SIX:ROG
276B CHF 4.5 29.4 12.5 14.5
UK
AstraZeneca PLC
LSE:AZN
216.8B GBP 0.1 0.3 0 0
CH
Novartis AG
SIX:NOVN
222.2B CHF 5 19.4 15.2 19.7
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16.1 11.2 13.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
NL
Pharvaris NV
NASDAQ:PHVS
Average P/E: 21.1
Negative Multiple: -8.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -157.8 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
0.3
37%
0
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.1
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
Pharvaris NV
NASDAQ:PHVS
Average EV/EBITDA: 45.5
Negative Multiple: -5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
0.4
36%
0
US
Johnson & Johnson
NYSE:JNJ
17.1
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
0
10%
0
CH
Novartis AG
SIX:NOVN
15.2
6%
2.5
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
Pharvaris NV
NASDAQ:PHVS
Average EV/EBIT: 99.7
Negative Multiple: -5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
1.9
98%
0
US
Johnson & Johnson
NYSE:JNJ
22.2
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
0
23%
0
CH
Novartis AG
SIX:NOVN
19.7
12%
1.6
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5